Background Antiarrhythmic drugs are known to have statedependent interactions with cardiac sodium channels, and these have potentially important implications for drug effects on cardiac conduction, particularly in situations of changed resting potential and heart rate. Recent advances in theoretical approaches permit beat-to-beat changes in sodium channel block to be inferred from conduction changes in vivo and allow for an analysis of state-dependent drug action from conduction changes occurring on the onset of pacing at different rates. The purpose of the present study was to use this method to analyze the interaction between hyperkalemia and procainamide's sodium channel-blocking action in terms of resulting changes in left ventricular conduction.
,umol/L). The onset of conduction slowing and block followed basic molecular theory, with an exponential time constant that was faster at longer cycle lengths and total block that increased as cycle length decreased. Piecewise exponential analysis of block during the rested and depolarized phases of the action potential showed that the enhancement of procainamide's action by hyperkalemia was due almost exclusively to increased rested-phase block. Hyperkalemia produced a bradycardia-dependent and slight reduction in action potential duration and antagonized the action potential-prolonging effect of procainamide, particularly at shorter cycle lengths. Conclusions Hyperkalemia strongly enhances procainamideinduced conduction slowing by increasing the interaction between the drug and sodium channels during the rested phase of the cardiac cycle. These results indicate the applicability of basic molecular theories of antiarrhythmic drug action to understanding drug-induced changes in conduction velocity in vivo and highlight the potential importance of heterogeneous magnification of sodium channel-blocking drug action by the spatially variable hyperkalemia that occurs with acute myocardial ischemia. The latter could play an important role in the known proarrhythmic potential of sodium channel-blocking drugs in patients with coronary artery disease. (Circulation. 
Methods
Experiments were performed on 14 mongrel dogs of either sex weighing 15 to 20 kg that were anesthetized with morphine (2 mg/kg IM) and a-chloralose (100 mg/kg IV). A Harvard Apparatus respirator provided mechanical ventilation through an endotracheal tube at a rate of 10 breaths per minute. Arterial blood gases and pH were monitored routinely and maintained in the normal range (pH 7 computation of the relative conduction times to each electrode site for different activations as previously described. 16, 17 Drug Administration
Loading and maintenance-dose infusion regimens were applied as in previous reports17 to produce a series of stable procainamide concentrations. As many as three loading doses of 50 mg/kg IV were given, followed by maintenance dosages of 12, 24, and 36 mg-kg`. h`after 1, 2, or 3 loading doses, respectively. Electrophysiological studies were begun 20 minutes after the onset of each maintenance infusion. If conduction time at a cycle length of 300 milliseconds was prolonged by at least 20% relative to control, the entire study was performed during that maintenance infusion. On the other hand, if drug-induced conduction slowing was <20%, the next loading dose was administered. This procedure was repeated until a dose was found that increased conduction time by >20%. Blood samples for procainamide concentration measurement by high-performance liquid chromatography16 were drawn before and after electrophysiological studies for confirmation of the stability of drug concentrations.
Experiments were performed in seven normokalemic control dogs and in seven dogs with hyperkalemia produced by systemic infusion of potassium chloride. Stable hyperkalemia with approximately twice control serum potassium concentration was produced by a loading dose of 1 mEq/kg administered as a 0.6 to 0.8 mEq/min IV infusion over 25 minutes, followed by a maintenance dose of 0.3 to 0.5 mEq/min IV. Serum potassium concentration was measured periodically during the study with an ion-sensitive electrode on a multichannel analysis system (Astra-8, Beacham Inc), and values were stable over time (Fig 1) .
Experimental Protocol and Kinetic Analysis
The kinetics and magnitude of procainamide-induced conduction slowing were assessed with the use of experimental protocols and analysis techniques described in detail previously. 17 Briefly, pacing was initiated at a selected cycle length after a prolonged pause that averaged 7.2+0.4 seconds. An 8-second window of activation data was recorded, along with MAPs over the same interval. Conduction times and velocities were determined subsequently from activation maps constructed off-line.
To estimate procainamide association (k) and dissociation (1) constants during the depolarized (ka, la) and resting (kr, 4,) phases of the action potential, we determined characterizing 
Results
The infusion of potassium chloride caused an approximate doubling in serum potassium concentration (Table 1), with concentrations remaining constant through the study period (Fig 1) . The first loading dose (50 mg/kg) was sufficient to produce >20% conduction slowing in all hyperkalemic dogs, whereas in normokalemic dogs, two doses (total of 100 mg/kg) were required in five dogs and three doses (150 mg/kg) were required in the other two. Correspondingly, lower procainamide concentrations were required to produce perceptible degrees of conduction slowing in the presence of hyperkalemia (Table 1) . Despite these lower plasma drug concentrations, conduction was considerably more slowed in the presence of hyperkalemia (Fig  2) . Although conduction times were not significantly altered by hyperkalemia per se (Fig 2) , procainamide increased conduction time to a much greater extent in the presence of elevated potassium concentration.
A key step in the estimation of kinetic interactions with the sodium channel is the observation of the onset of block following a pause permitting drug unbinding.12-'4"17 Fig 3 shows the onset of procainamide-induced conduction slowing in one normokalemic dog. Changes in conduction time, as measured from the first to the last point activated in the electrode array, are shown at the upper left (Fig 3A) . Changes in longitudinal conduction velocity, as measured from the activation of three consecutive electrodes along the line of rapid propagation, are shown in Fig 3B. Fig 3C and 3D show the onset of sodium channel block, as calculated based on changes in conduction time ( Fig 3C) and conduction velocity (Fig 3D) , respectively. The mathematical approach to estimating kinetic variables is described in detail in previous theoretical12'13 and experimental'4"7 articles and will not be repeated here. The overall approach is illustrated in Fig  6. The cell is conceived of as cycling between two drug affinity states: a high-affinity state following activation and designated a (in the case of procainamide, corresponding to the period of channel inactivation during the action potential plateau), and a low-affinity state designated r when the cell is not activated. These correspond to the depolarized and rested phases of the cardiac electrical cycle, respectively. Interaction with the high-affinity state is characterized by a rate constant of Aa, whereas interaction with the low-affinity state has a rate constant of Ar. The kinetic variables calculated for procainamide from conduction time changes in the present experiments are shown in Table 2 . Although maximal steadystate block in the high-affinity state (aJ is increased by 20% in the presence of hyperkalemia, steady-state block during electrical diastole (r-) is increased by more than 170% (despite lower drug concentrations in the presence of hyperkalemia). This increase in steady-state diastolic block is due predominantly to an almost fourfold increase in the forward rate constant for diastolic block (kr).
Based on the calculated kinetic constants and proportion of time in the rested and depolarized phases of the cardiac cycle, it is possible to estimate the fraction of Results were obtained at five basic cycle lengths (BCLs) (300 milliseconds, o; 400 milliseconds, *; 500 milliseconds, A; 600 milliseconds, *; 800 milliseconds, c).
The onset of drug-induced sodium channel block was estimated from changes in CT (C) and CV (D), assuming a squared relation between CV and sodium current. Results were well fit by single exponential equations (lines shown), with rate constants (A*) shown. As predicted from underlying theory, the onset of block was more rapid at longer BCLs. Beat Number (n) channel block at any rate that is due to interaction during each phase. For each, block will be proportional to the product of the rate constant for block onset, the time during each cycle occupied by that phase, and the corresponding steady-state block (ie, a. and r.). Fig 7 shows the results of this analysis. As shown on the left, hyperkalemia did not substantially alter the plateauphase block (ba) caused by procainamide. In contrast, hyperkalemia substantially increased the rested-phase block (br, middle). Hyperkalemia-induced increases in rested-phase block were greatest at long cycle lengths, at which depolarized-phase block is the least. Consequently, the result of hyperkalemia is to increase the proportion of total block due to association with the rested phase. Fig 7 (right) shows the ratio of rested-to depolarized-phase block (br/ba) in hyperkalemic and normokalemic dogs as a function of cycle length. In normokalemic dogs, rested-phase block is much smaller than depolarized-phase block at all cycle lengths. Hyperkalemia significantly increases the importance of rested-phase block at all cycle lengths, with the relative importance of rested-phase block increasing substantially with increasing cycle length to the point that resting-phase block contributes almost as much as depolarized-phase block at a cycle length of 1000 milliseconds. Table 2 shows that hyperkalemia produces a small, but statistically significant, increase in maximal steadystate plateau block (a.) due to procainamide. One Beat Number (n) mic dogs than in normokalemic dogs. Consequently, the amount of time available for drug binding to the plateau state was reduced by hyperkalemia. Finally, the estimated rate constant for plateau block (Aa) was reduced by hyperkalemia ( Table 2 ), so that for a given plateau duration a smaller percentage of maximal plateau-state block was achieved by the drug.
Discussion
We have shown a strong interaction between moderate hyperkalemia and the conduction-slowing properties of procainamide in vivo. Sodium channel blockade, as inferred from conduction changes, was increased in a rate-dependent fashion, primarily because of an increased interaction with channels during the resting phase of the cardiac cycle. The magnitude and dynamic beat-to-beat blocking properties followed the predictions of basic theoretical models.7-14
Comparison With Previous Studies in the Literature
Interactions between extracellular potassium concentrations and antiarrhythmic drug action have long been recognized.' Hyperkalemia is known to enhance the Vma,-suppressant properties of sodium channel-blocking antiarrhythmic drugs2l82425 by voltage-dependent enhancement of state-dependent channel blockade.7-1" Relatively less research has been done to examine the might therefore expect hyperkalemia to augment both plateau and diastolic sodium channel block. Fig 7A  shows , however, that plateau sodium channel block was not increased by hyperkalemia. This finding can be explained by three factors. First, hyperkalemia reduced action potential duration (APD) at slower rates (Fig 8,  top) . Second, hyperkalemia antagonized the APD-prolonging properties of procainamide (Fig 8, bottom) , such that APD was increased significantly less by the drug, particularly at shorter cycle lengths, in hyperkale- modulation of drug effects on conduction by changes in serum potassium concentration. Cascio et a16 demonstrated that hyperkalemia enhances procainamide-induced conduction slowing. They did not, however, attempt to analyze the changes in drug interaction with the sodium channel that underlie the synergistic interaction that they observed. We observed (Fig 2) , as did Cascio et al,6 that drug-induced conduction-time prolongations are substantially greater at faster activation rates in the presence of hyperkalemia. This observation could lead to the erroneous conclusion that hyperkalemia enhances procainamide action selectively when the cell is activated. As shown in Fig 7, hyperkalemia selectively increases rested-phase block by procainamide, as one would predict based on a mechanism related to depolarization of the resting potential.6-14 The increase in rested-phase block increased total steady-state block at all cycle lengths (Fig 5) and caused the enhanced rate-dependent conduction slowing shown in Fig 2. Like Sada et al,18 who analyzed the interactions between [K']e and procainamide in guinea pig papillary muscles studied with standard microelectrodes, we found that hyperkalemia enhances the sodium channelblocking actions of the drug without significantly altering recovery kinetics (reflected by 1/A, in the present study). The mean procainamide recovery time constant was in the range of 2 seconds for both normokalemic and hyperkalemic dogs, of the same order as observed in previous in vitro18,2326 and in vivo1617 studies. The procainamide rate constants obtained for normokalemic dogs in the present study are of the same order as those noted in our previous series, in which conduction analysis was based on a sock array covering the epicardial surfaces of both ventricles,17 and are similar to results obtained by Sada et al with Vmax as an index of INa in vitro.18 As previously noted in cellular studies,27 we found that hyperkalemia reduced APD in a bradycardia-dependent fashion (Fig 8, top) . We also found that hyperkalemia attenuated drug-induced APD changes (Fig 8, bottom) , an observation consistent with previous in vitro studies of the interactions between antiarrhythmic drug effects and changes in [K+Ie. 18'25 Potential Importance of Findings
We have shown that even moderate hyperkalemia strongly enhances the conduction-slowing actions of procainamide. Despite much smaller plasma drug concentrations in hyperkalemic dogs, which averaged 36% of the values in normokalemic animals, procainamide increased conduction times to a much greater extent in the presence of hyperkalemia (Fig 2) . We were able to relate the enhancement of procainamide's action by hyperkalemia to differential changes in interactions between the drug and sodium channels during the rested and depolarized phases of the cardiac cycle. Our results suggest that hyperkalemia increases procainamide's conduction-slowing action by increasing block during the resting phase of the cardiac cycle. These observations are consistent with the concept that the increased drug action caused by hyperkalemia is due to a reduction in the resting membrane potential, favoring sodium channel inactivation. The latter promotes drug binding to the channel either by promoting a true high-affinity state9,10 or by increasing access to, and limiting egress from, the depolarized inactivated state.8 Mathematical models of sodium channel blockade9'12-14 have provided useful insights into potential interactions between antiarrhythmic drugs and the sodium channel at the molecular level. Our previous studies showed that these concepts could be applied to analyze the kinetics of drug effects on ventricular conduction during paired-pulse16 and sustained-pacing17 protocols in anesthetized dogs. The present study extends these observations to the quantitative analysis of drug-induced conduction slowing in the presence of varying [Kj]e in vivo.
Study Limitations
Changes in drug-induced conduction slowing in vivo are, at best, an indirect indicator of varying interactions with sodium channels. We are not proposing that this approach be put forward as a way of analyzing drugreceptor interactions at the molecular level; rather, we show that inferences can be made about such interactions based on in vivo conduction changes and that the conclusions are in agreement with theoretical predictions and with observations at the cellular level. Our findings reinforce the relevance of basic theories about drug action on sodium currents for the detailed understanding of their effects on macroscopic properties like conduction in vivo. We were not able to cause more severe hyperkalemia while maintaining dogs in a sufficiently stable condition to perform the protocols necessary for detailed quantitative analysis. Our analysis is therefore limited to the moderate hyperkalemia (doubling of [K+Ie) that might occur in the border zone of an acute infarction. The creation of regional hyperkalemia by intracoronary infusion of potassium might be an interesting approach to studying in more detail the interactions among various levels of hyperkalemia, drug-induced conduction changes, and sodium channel-blocking action.
Throughout this article, we have referred to block during the depolarized phase of the action potential as "depolarized-phase block" and to block between depolarizations as "rested-phase block." The latter should not be equated with rested-state block. Because hyperkalemia results in depolarization, a substantial portion of the block occurring during the resting phase of the cardiac cycle may be due to interaction with inactivated channels.
Conclusions
We have shown that moderate hyperkalemia strongly increases the rate-dependent conduction-slowing action of procainamide. Quantitative analysis suggests that the potentiation of drug action is due predominantly to enhancement of block during the resting phase of the cardiac cycle. This is the first study to apply theoretical models to the analysis of drug-sodium channel interaction underlying drug-induced conduction slowing in the presence of a component of acute myocardial ischemia, extracellular hyperkalemia. It demonstrates the applicability of this type of analysis and suggests its potential relevance to understanding drug action in the presence of derangements of the extracellular milieu and pathological cardiac states.
